BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8

March 5, 2018 8:10 AM

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 5, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss financial results for the calendar year ended December 31, 2017, and provide important corporate updates.

Logo - hi-res

BrainStorm's senior management team, including Chaim Lebovits, CEO, Ralph Kern, M.D., MHSc, COO & CMO, and Eyal Rubin, CFO, will host a conference call and webcast for the investment community on Thursday, March 8 at 8:30am Eastern.

Thursday, March 8, 2017 @ 8:30am Eastern Time

TOLL-FREE: 1-800-289-0438

TOLL/INTERNATIONAL: 1-323-794-2423

ISRAEL TOLL-FREE: 1809 212 883Webcast link:

Replays, available through March 22, 2018

Replay Dial-In Numbers:

TOLL-FREE: 1-844-512-2921

TOLL/INTERNATIONAL: 1-412-317-6671

Replay Pin Number: 3071165About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at


Media:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: (646)

Investors:Michael RiceLifeSci Advisors, LLCPhone:

Cision View original content with multimedia:

SOURCE BrainStorm Cell Therapeutics Inc.


Press Releases